Form 4: Director CeCelia Morken Receives Genpact RSU Grant

Director CeCelia Morken was granted 6,521 restricted share units (RSUs) as part of the Genpact Limited 2017 Omnibus Incentive Compensation Plan.

Summary

• Director CeCelia Morken acquired 6,521 restricted share units (RSUs) on April 23, 2026.
• The grant was issued under the Genpact Limited 2017 Omnibus Incentive Compensation Plan.
• Following this transaction, Morken's total beneficial ownership of common shares stands at 64,281.
• The RSUs are subject to continued service requirements and will fully vest on December 31, 2026, with settlement occurring on December 31, 2027.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative disclosure regarding routine director compensation.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• None identified; this is a standard equity compensation disclosure.

Risks

• Vesting is contingent upon the reporting person's continued service to the company.

Future Outlook

The RSUs are scheduled to vest on December 31, 2026, and settle in common shares on December 31, 2027, provided the director remains in service.

Industry Context

StockSavvy.ai notes that equity grants to independent directors are a standard corporate governance practice in the IT services and consulting sector to ensure board members maintain a vested interest in company performance.

Comparison to Industry Standards

• The use of 2017 Omnibus Incentive Compensation Plans is consistent with standard equity retention programs at large-cap technology and consulting firms like Accenture or Infosys.

Stakeholder Impact

• Minimal impact on shareholders as this is a standard compensation event.

Next Steps

• Vesting of RSUs on December 31, 2026.
• Settlement of shares on December 31, 2027.

Key Dates

Keywords

Genpact, G, Form 4, Insider Trading, Equity Compensation, Restricted Share Units, Director Compensation